OIS@AAO 2017 Videos

Kala

Kala Expects Dry Eye Data by 2017 Year-end

By Mario Admin | December 8, 2017

Kala Pharmaceuticals is expecting by the end of 2017 topline clinical data from its ongoing Phase III trial of KPI-121 0.25% for treatment of dry…

Read More
Clearside

Clearside Eyes Major Milestones in 2018-19

By Mario Admin | December 8, 2017

Clearside Biomedical has a full agenda of major near-term milestones in the development of its suprachoroidal CLS-TA (triamcinolone-acetonide) platform in 2018 and 2019, president and…

Read More
Alimera

Alimera Sees Black for 2018

By Mario Admin | December 8, 2017

Alimera Sciences’ Iluvien insert for treatment of diabetic macular edema is making headway in the market, CEO Dan Myers said at the Company Showcase 3…

Read More
Aerie

Aerie Plans Next Step after Rhopressa

By Mario Admin | December 8, 2017

Even though its PDUFA date for the glaucoma agent Rhopressa is set for February 2018, Aerie Pharmaceuticals is moving forward on development of its age-related…

Read More
Notal Vision

Notal Vision Sets Launch of Second Home-based Device

By Mario Admin | December 8, 2017

Notal Vision is set to launch its second product, home-based optical coherence tomography (OTC) for monitoring of retinal fluid accumulation in patients with retinal disease,…

Read More
Ocular

Ocular Therapeutix to Refile Dextenza NDA

By Mario Admin | December 8, 2017

Ocular Therapeutix is gearing up to resubmit in the first half of 2018 its New Drug Application for its Dextenza 0.4-mg dexamethasone insert, president and…

Read More
Gray bug

Graybug Expects Initial Data in Q2 2018

By Mario Admin | December 8, 2017

Graybug Vision’s ongoing Phase I/II trial or GB-102 (1 mg sunitinib) injection for wet age-related macular degeneration should produce initial six-month data in Q2 2018,…

Read More
Allegro

Allegro Plans for Phase III of Luminate

By Mario Admin | December 8, 2017

Allegro Ophthalmics is planning a 2018 Phase III trial of its lead integrin peptide therapy candidate Luminate for treatment of diabetic macular edema, president Vicken…

Read More
Ocunexus

Ocunexus Seeking Support for Phase IIb of Oral GA Agent

By Mario Admin | December 8, 2017

Ocunexus Therapeutics’ CEO Brian Levy, OD, MSc, provided an update on Ocunexus Therapeutics’ two lead candidates during the Company Showcase 3 session at OIS@AAO 2017.…

Read More
KalVista

KalVista Provides Update on Merck Collaboration

By Mario Admin | December 8, 2017

During the Company Showcase 3 session at OIS@AAO 2017 KalVista Pharmaceuticals CEO Andrew Crockett provided an update on the company’s collaboration with Merck for KVD001,…

Read More
Aerpio

Aerpio Looks to Take Lead Agent Beyond DR

By Mario Admin | December 8, 2017

In developing the small-molecule agent AKB-9778 to target the Tie2/VE-PTP pathway, Aerpio president and CEO Joseph Gardner, PhD, said the first-in-class agent that inhibits phosophatase…

Read More
ONL therapeutics

ONL Therapeutics Looks to IND in 2018

By Mario Admin | December 8, 2017

ONL Therapeutics is using the $5 million in Series A funding it obtained in May 2017 to complete and file the investigational new drug application…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.